Skip to content

Effect of Mobile Health-Supported Integrated Lifestyle Intervention on Metabolic Improvement in Xinjiang Residents at Risk of Cardio-Cerebrovascular Diseases

Effect of Mobile Health-Supported Integrated Lifestyle Intervention on Metabolic Improvement in Xinjiang Residents at Risk of Cardio-Cerebrovascular Diseases - MILIV Study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500112575
Enrollment
Unknown
Registered
2025-11-17
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Risk factors for cardiovascular and cerebrovascular diseases

Interventions

Intervention group:Use the full-feature "Jiangxin Health" WeChat Service Account: receive standardized information on chronic disease management through WeChat Service Account every week
Record three meals by taking photos every day, and the system automatically identifies food types and calculates calorie intake
Record daily exercise synchronously through manual input or smart wristbands
WeChat Service Account sends intelligent alerts and improvement recommendations, such as: "Today's vegetable intake is insufficient, it is recommended to add a green leafy vegetable" and other target
control group:Use the basic version of "Jiangxin Health" WeChat Service Account: receive standardized information on chronic disease management through WeChat Service Account every week
There is no intelligent alerts and improvement recommendations. For the control group, the monthly data will export, but no active intervention will carry out. All participants receive standardized he

Sponsors

The First Affiliated Hospital of Xinjiang Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age between 45 and 75, regardless of sex; 2. Having one or more risk factors for cardiovascular and cerebrovascular diseases: a. hypertension: systolic blood pressure >=140 mmHg and/or diastolic blood pressure >= 90mmhg; b. Diabetes: fasting blood glucose >=7.0 mmol/L or 2 hours postprandial blood glucose >= 11.1 mmol/L; c. dyslipidemia: total cholesterol >=5.2 mmol/L or low-density lipoprotein cholesterol >=3.1 mmol/L or high-density lipoprotein cholesterol = 1.7 mmol/L; d. Overweight/obesity: BMI>=24 kg/m^2 or waist circumference >=90 cm for men and >=85 cm for women. 3. Can use smart phones and other devices with unlimited Internet access, and is willing to use wearable devices; 4. Voluntary participation and signing of informed consent.

Exclusion criteria

Exclusion criteria: 1. Severe cardiovascular and cerebrovascular diseases (such as heart failure, myocardial infarction, stroke, acute myocarditis, interventional therapy, etc. in the past 6 months) and severe arrhythmia (any of the following arrhythmia has not been treated: >=Mobitz type II second-degree atrioventricular block; Atrial fibrillation or flutter; Ventricular tachycardia and ventricular fibrillation; Paroxysmal supraventricular tachycardia); 2. Stage III hypertension (SBP cannot be controlled below 160 mmHg with three antihypertensive drugs); 3. Severe liver and kidney function diseases (alanine aminotransferase and serum creatinine indexes exceed the normal range set by the hospital by 4 times); 4. Patients with serious diseases such as malignant tumors and hematological diseases; 5. Infectious diseases such as hepatitis B, active tuberculosis and AIDS; 6. Persons with impaired physical activity or those with limited physical activity due to diseases and treatments; 7. Women who are pregnant or breastfeeding, or who have a pregnancy plan in the next 6 months; 8. People who are mentally ill and can't cooperate well; 9. It is planned to move to an area where follow-up cannot be carried out during the study; 10. other circumstances that the researcher thinks are not suitable for the group; 11. Refuse to participate in this study or sign an informed consent form.

Design outcomes

Primary

MeasureTime frame
blood pressure;

Secondary

MeasureTime frame
heart rate;body weight;waist circumference;hip circumference;glycated hemoglobin (HbA1c); fasting plasma glucose;Total Cholesterol (TC);Low-Density Lipoprotein Cholesterol (LDL-C);High-Density Lipoprotein Cholesterol (HDL-C);Triglycerides (TG);serum uric acid;mean daily caloric intake;cardiovascular risk score(CHINA-PAR);Intervention satisfaction score;Exercise Adherence;Dietary Adherence;

Countries

China

Contacts

Public ContactBaopeng Tang

Department of Pacing and Electrophysiology, The First Affiliated Hospital of Xinjiang Medical University

tangbaopeng1111@163.com+86 135 7988 1111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026